MedTrace Logo

Treatment of Psychotic Major Depression With Mifepristone

NCT00867360 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-04-04

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to see how certain hormones cause changes in mood and thinking in some depressed patients and to determine the effectiveness of mifepristone in treating some forms of depression.

This study is conducted in conjunction with an observational study "Clinical and Biological Characteristics of Psychotic Depression".

Conditions

  • Affective Disorders, Psychotic
  • Depressive Disorder

Interventions

DRUG

Mifepristone (RU-486)

DRUG

Placebo

Placebo medication

Sponsors & Collaborators

Principal Investigators

  • Fredric B Kraemer · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00867360 on ClinicalTrials.gov